Nature reviews. Clinical oncologyHumansCarcinomaNon-Small-Cell LungDrug ResistanceNeoplasm
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches.
Jing Zhao, Wanting Xu, Fei Zhou, Xiangyu Zhang, Mo Zhou, Da Miao, Lan Yu, Yongchang Zhang, Junqiang Fan, Caicun Zhou, Wen Li, Tony Mok, Xiuning Le, Molly Li, Yang Xia
Published: 202610.1038/s41571-025-01085-z
Abstract
Resistance to EGFR tyrosine kinase inhibitors (TKIs) remains a major obstacle in the clinical management of EGFR-mutant non-small-cell lung cancer (NSCLC). Despite the transformative therapeutic activity of the multiple iterations of EGFR TKIs, spann…
Preview only. Read the full abstract at the source